Review Finds No Significant Breast Cancer Risk Increase in GLP-1 Trials, Calls for Further Research

Randomised trial evidence has not shown a significant increase in breast cancer risk among people receiving GLP-1 receptor agonists, according to a narrative review published in Frontiers in Pharmacology. However, the review does not establish that these medicines prevent or treat breast cancer.

The authors examined research on drugs used for type 2 diabetes and obesity, including liraglutide and semaglutide, alongside the dual GLP-1/GIP receptor agonist tirzepatide. Their analysis brings together laboratory experiments, animal studies and clinical evidence.

According to Frontiers in Pharmacology, a meta-analysis covering 52 trials with breast cancer events reported a relative risk of 0.98, with a 95% confidence interval of 0.76 to 1.26. The review notes that the trials had relatively short follow-up and were not designed with sufficient statistical power to settle cancer outcomes.

The authors organise the evidence around three factors: the molecular subtype of breast cancer, the amount of drug exposure and the individual’s metabolic condition. They argue that these distinctions are essential when interpreting apparently conflicting findings.

Laboratory studies have produced different results under different conditions, the review reported. Some experiments linked liraglutide to increased growth in breast cancer models, particularly at exposures exceeding those typically reached during clinical treatment.

In triple-negative breast cancer models, high-dose liraglutide activated a pathway involving NOX4, reactive oxygen species and VEGF. The review cautions against treating findings at these experimental exposures as evidence of equivalent effects in patients.

Other experiments found reduced cancer-cell growth. According to Frontiers in Pharmacology, exendin-4 inhibited growth in certain breast cancer cell lines through suppression of NF-kappaB activity. Experiments combining exendin-4 with metformin also recorded reductions in tumour weight and markers of cell proliferation in animal models.

Liraglutide showed growth-inhibiting effects in another laboratory setting involving breast cancer cells exposed to material derived from obese adipose tissue. Those findings were associated with changes in metabolism, inflammatory mediators and hormones released by fat tissue, the review reported.

These results remain preclinical. The authors conclude that they do not justify describing the entire drug class as either promoting or suppressing breast cancer.

The review also examines possible indirect effects through weight loss and improved insulin sensitivity. Obesity, elevated insulin and inflammation are linked to biological processes involved in breast cancer, providing a rationale for investigating metabolic treatments.

However, according to Frontiers in Pharmacology, improvements in systemic metabolism have not established a corresponding anticancer effect in patients. Proposed changes to immune activity around breast tumours require direct validation.

Observational studies have also produced varying risk estimates. The review identifies confounding and detection bias as important limitations, including the possibility that weight loss changes how readily breast cancer is detected.

Comparisons between individual medicines are similarly uncertain. The authors say observational differences do not establish that one agent is preferable to another on cancer-related grounds.

The publication itself is a narrative review based on targeted literature searches and citation tracking, rather than a formal systematic review or a new quantitative analysis.

Its research priorities include prospective studies combining metabolic measurements with tumour samples and immune profiling. According to Frontiers in Pharmacology, these approaches are needed to distinguish established treatment effects from plausible mechanisms and determine their relevance to breast cancer.

Sources

• Context-dependent pharmacological effects of GLP-1 receptor agonists in breast cancer from molecular mechanisms to clini